Targeted therapies such as sunitinib, vismodegib, and HER2 inhibitors have been explored, as well as pembrolizumab for programmed cell death protein ligand 1 positive metastatic disease, though with limited success.14 Here, ERBB2 is linked to metastatic neoplasm.